Menlo Therapeutics announces results from Phase 2 trial for serlopitant

Menlo Therapeutics announced results from its Phase 2 clinical trial evaluating the safety and efficacy of once daily oral serlopitant for the treatment of chronic pruritus of unknown origin. The trial, which included 233 patients, did not meet its primary endpoint to show a statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. In the trial, 37.9% of patients in the serlopitant group achieved a 4-point or greater improvement on the worst-itch numeric rating scale, or WI-NRS, at week 10 compared to baseline versus 39.3% of patients treated with placebo. There were no meaningful differences observed between the serlopitant and placebo groups in the prospectively-defined secondary endpoints. The Phase 2 multicenter, placebo-controlled double-blind clinical trial enrolled 233 patients with self-reported CPUO, who experienced pruritus for at least six months prior to enrollment with no identified underlying cause for the pruritus. This trial compared treatment with serlopitant versus placebo for 10 weeks. Serlopitant was well-tolerated. The frequency of treatment-emergent adverse events assessed as likely related to treatment were 10.3% in the serlopitant group versus 2.6% in the placebo group. The most frequently reported adverse events in the serlopitant group were diarrhea, somnolence, fatigue and headache. The most frequently reported adverse events in the placebo group were gastroesophageal reflux disease and arthralgia. Two serlopitant-treated subjects reported a total of three serious adverse events which were deemed to not be related to study drug. To date, serlopitant has been administered to over 2,000 individuals, including patients who have received treatment for up to one year. Results from the company's Phase 3 trials for the treatment of pruritus associated with prurigo nodularis are expected in March or April of this year.